How does canakinumab prevent IL-1 beta-induced gene activation and inflammatory mediator production?

Canakinumab binds specifically and with high affinity to human IL-1 beta, neutralising its biological activity by blocking its interaction with IL-1 receptors, thereby preventing IL-1 beta-induced gene activation and inflammatory mediator production.